For example, miR-146a attenuates pro-inflammatory signaling by directly targeting IRAK1 and TRAF6, key adapters in TLR/NF-κB pathways—mechanistically linked to reduced secretion of IL-6 and TNF-α in epithelial and myeloid systems, a paradigm broadly applicable to tumor contexts [25,26]. Here, NFKB1 is linked to neoplasm.